Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two‐Centre Open, Single‐Arm Trial
ABSTRACT Background With the elevated level of NAFLD prevalence, the incidence of diabetes, hypertension, metabolic syndrome and other diseases is also significantly elevated. GLP‐1RA can exert weight loss, glucose‐lowering effects and various nonglycaemic effects. However, the relationship between...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Endocrinology, Diabetes & Metabolism |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/edm2.70021 |